<DOC>
	<DOC>NCT02456688</DOC>
	<brief_summary>This clinical research study will assess pharmacokinetics and the safety of Imrecoxib in patients with impaired hepatic function as compared to healthy volunteers.</brief_summary>
	<brief_title>Pharmacokinetics of Imrecoxib in Subjects With Hepatic Insufficiency</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>All subjects: Between the ages of 18 to 70 years, with BMI 18~ 29kg/m2. In good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory test values(except for values related to hepatic insufficiency). Hepatic impaired subjects: Hepatocirrhosis subjects verified by Bmode ultrasonography,CT ,MRI or Biopsy. A ChildPugh Classification score clinically determined as Class B. All subjects: History of hypersensitivity to Imrecoxib or its components. Subjects diagnosed with tumor. History of or current clinically important systemic illnesses, including but not limited to cardiovascular, pulmonary, renal, hematological, gastrointestinal, endocrinological, immunological, dermatological, or psychiatric diseases. Have used any drugs or substances (including herbal supplements) known to inhibit or induce cytochrome P450 enzymes including cytochrome P450 3A4, cytochrome P450 2C8 and cytochrome P450 2C9 within 28 days prior to the first dose and throughout the study. Have taken other investigational drugs or participated in any clinical trial within 90 days prior to first dose of study drug in this study. Hepatic impaired subjects: Subjects with hepatic failure,or severe complications caused by Hepatocirrhosis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>